Dina Masi - Integrated Biopharma CFO, Sr. VP and Secretary
| INBPDelisted Stock | USD 0.23 0.01 4.55% |
CFO
Ms. Dina L. Masi serves as Chief Financial Officer, Senior Vice President, Secretary of Integrated BioPharma, Inc. Ms. Masi joined the Company on November 17, 2005. Previously, Ms. Masi most recently operated a financial services consulting firm, DLM Accounting and Financial Services, LLC, providing accounting and financial services to small business owners and SEC registrants from May 2005 to November 2005. From June 2002 to December 2004, Ms. Masi served as the Chief Financial Officer and Senior Vice President of Prescott Funding, LLC, a licensed residential mortgage lender specializing in nonconforming consumer lending since 2005.
| Age | 62 |
| Tenure | 19 years |
| Phone | 888 319 6962 |
| Web | https://www.ibiopharma.com |
Integrated Biopharma Management Efficiency
The company has return on total asset (ROA) of 0.0336 % which means that it generated a profit of $0.0336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Integrated Biopharma's management efficiency ratios could be used to measure how well Integrated Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 53 K in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Integrated Biopharma has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Integrated Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Integrated Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Integrated Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Integrated to invest in growth at high rates of return. When we think about Integrated Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | CFO Age | ||
| Dennis Riordan | Treehouse Foods | 58 | |
| Frederic Pflanz | Aryzta AG PK | 50 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 |
Integrated Biopharma Leadership Team
Elected by the shareholders, the Integrated Biopharma's board of directors comprises two types of representatives: Integrated Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integrated. The board's role is to monitor Integrated Biopharma's management team and ensure that shareholders' interests are well served. Integrated Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integrated Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riva Sheppard, Executive Vice President Director | ||
| Robert Canarick, Independent Director | ||
| Carl DeSantis, Director | ||
| William Milmoe, Director | ||
| Schild OBE, Chief iBioPharma | ||
| Dina Masi, CFO, Sr. VP and Secretary | ||
| Nickolas Palin, Pres Segment | ||
| Robert Erwin, Pres iBioPharma | ||
| Gerald Kay, Chairman, CEO and Pres | ||
| Joseph LaPlaca, Director | ||
| Jamie Levey, Head Relations | ||
| Christina Kay, Executive VP and Director | ||
| Orn Adalsteinsson, Chief Inc |
Integrated Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Integrated Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Shares Owned By Insiders | 68.58 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Integrated Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Integrated Biopharma's short interest history, or implied volatility extrapolated from Integrated Biopharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |